Related Experiment Video

Updated: Aug 22, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

[What is confirmed in the treatment of atrial fibrillation?]

Volker Liebe1, Mathieu Kruska2, Daniel Dürschmied2

  • 1I. Medizinische Klinik, Kardiologie, Angiologie, Hämostaseologie und Internistische Intensivmedizin, Universitätsklinikum Mannheim GmbH, 68135, Mannheim, Deutschland. volker.liebe@umm.de.

Innere Medizin (Heidelberg, Germany)
|November 10, 2022
PubMed

Insights

Atrial fibrillation (AF) treatment now emphasizes the 4S-AF scheme for risk stratification and symptom control. Rhythm-maintaining strategies like catheter ablation are increasingly favored over rate control for better quality of life.

Area of Science:

  • Cardiology
  • Clinical Medicine

Context:

  • Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
  • Current treatment goals include improving quality of life, symptom relief, and stroke prevention.

Purpose:

  • To outline the updated European guidelines for atrial fibrillation management from 2020.
  • To introduce the 4S-AF scheme for comprehensive AF characterization and treatment planning.
  • To highlight the shift towards rhythm-maintaining therapies.

Summary:

  • The 2020 European guidelines introduce the 4S-AF scheme (Stroke risk, Symptoms, AF burden/substrate) for structured AF assessment.
  • Anticoagulation decisions require thorough risk stratification.
  • Treatment planning prioritizes symptom control, with rhythm-maintaining strategies (pharmacological or catheter ablation) gaining precedence over rate control.
  • Management also includes addressing comorbidities, cardiovascular risk factors, and lifestyle modifications.

Impact:

  • Provides a structured framework for clinicians to manage atrial fibrillation effectively.
  • Promotes personalized treatment strategies based on individual patient profiles.
  • Emphasizes the growing importance of rhythm control and integrated care in AF management.

Keywords:
AnticoagulantsAtrial fibrillation/characterizationCatheter ablationLifestyleRisk stratification

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
32
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
89
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
235